Christer F?hraeus, founder and CEO, has announced to the board of EQL Pharma AB that he wishes to continue his work for the company in a pure board capacity after the next Annual General Meeting of the company, scheduled for August 15, 2022. The board has therefore on November 10, 2021 agreed with Axel Sch?rling, deputy CEO, that he will take over the position as CEO for EQL Pharma AB starting after the next Annual General Meeting. Christer will remain CEO until this time, and then intends to be active as a board member and owner. The background to the decision to name a new CEO earlier than usual is that it provides opportunities and time to prepare Axel Sch?rling to take over the role of CEO from Christer F?hraeus for. Axel Sch?rling has been the company's Chief Operating Officer since 2018, and he was appointed Deputy CEO in 2020. Therefore, the board of EQL Pharma sees this succession as well prepared and planned. Christer F?hraeus will continue to be highly active in the company, not only during the remainder of his tenure as CEO, but also afterwards in his capacity as a member of the board and as a committed major shareholder in the company. Christer F?hraeus has other corporate interests, not least through the investment company F?r? Capital AB and a startup Fund, and has expressed a desire to gradually reduce his daily and operational involvement in EQL Pharma AB, and therefore the succession to the CEO position has been planned for some time. Axel Sch?rling has previously worked as a management consultant in the global consulting business BearingPoint. Axel was also previously responsible for Operations Controlling in Perstorp Group AB. As Chief Operating Officer at EQL Pharma, Axel has been instrumental in the company's rapid growth.